Mount Sinai researchers involved in successful phase 3 trial of drug for liver cancer

(The Mount Sinai Hospital / Mount Sinai School of Medicine) An international phase 3 trial has found that the drug regorafenib improved survival in patients with advanced hepatocellular carcinoma, a form of liver cancer, giving people who previously had no other options a better chance at survival. Results from the study, which included researchers at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, were recently published in The Lancet. The trial, funded by Bayer, incl...